scholarly journals Effect of Bifidobacterium animalis subsp. lactis MN-Gup on constipation and the composition of gut microbiota

2020 ◽  
pp. 1-12
Author(s):  
R. Wang ◽  
J. Sun ◽  
G. Li ◽  
M. Zhang ◽  
T. Niu ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Controlled Trial ◽  
Functional Constipation ◽  
Short Chain Fatty Acids ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Human Faeces ◽  
Bifidobacterium Animalis ◽  
Defecation Frequency ◽  
Wet Weight

Probiotics have been reported to be associated with the alleviation of constipation. The aim of this study was to detect and determine the effect of Bifidobacterium animalis subsp. lactis MN-Gup (MN-Gup) on the alleviation of constipation in BALB/c mice and humans, and to elucidate the mechanisms underlying its effect by measuring changes in the concentration of short-chain fatty acids and the composition of microbes in human faeces. BALB/c mice were given MN-Gup by gavage for 14 days. On the 8th day of this treatment, constipation was induced by the application of diphenoxylate via gavage. The results showed that MN-Gup significantly decreased the first black stool defecation time, and significantly increased black faecal wet weight, black faecal number and the gastric-intestinal transit rate (P<0.05), thereby relieving constipation. In humans, a randomised, double-blind, placebo-controlled trial was performed to investigate the effect of MN-Gup in adults with functional constipation. After 4 weeks of intervention with placebo or MN-Gup yogurt, constipation-related symptoms (including defecation frequency, stool consistency, straining and incomplete feeling during defecation) in the constipated subjects were significantly improved in the two groups, but not different between the groups at the end of the intervention. The concentration of acetate increased significantly in the MN-Gup group compared to the placebo group and before ingestion. Significant changes in the composition of gut microbiota were found after intake of MN-Gup yogurt when compared to placebo. The relative abundances of acetate-producing Bifidobacterium, Ruminoccaceae_UCG-002 and Ruminoccaceae_UCG-005 were significantly increased after intake of MN-Gup yogurt. These results showed that MN-Gup could relieve constipation related to increased acetate-producing Bifidobacterium, Ruminoccaceae_UCG-002 and Ruminoccaceae_UCG-005.

scholarly journals Effect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12®, on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial

2015 ◽  
Vol 114 (10) ◽  
pp. 1638-1646 ◽  
Author(s):  
Dorte Eskesen ◽  
Lillian Jespersen ◽  
Birgit Michelsen ◽  
Peter J. Whorwell ◽  
Stefan Müller-Lissner ◽  
...  
Keyword(s):  
Controlled Trial ◽  
Probiotic Strain ◽  
Well Being ◽  
Abdominal Discomfort ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Bifidobacterium Animalis ◽  
Probiotic Treatment ◽  
Placebo Capsule ◽  
Defecation Frequency

AbstractThe aim of the present study was to investigate the effect of Bifidobacterium animalis subsp. lactis, BB-12®, on two primary end points – defecation frequency and gastrointestinal (GI) well-being – in healthy adults with low defecation frequency and abdominal discomfort. A total of 1248 subjects were included in a randomised, double-blind, placebo-controlled trial. After a 2-week run-in period, subjects were randomised to 1 or 10 billion colony-forming units/d of the probiotic strain BB-12® or a matching placebo capsule once daily for 4 weeks. Subjects completed a diary on bowel habits, relief of abdominal discomfort and symptoms. GI well-being, defined as global relief of abdominal discomfort, did not show significant differences. The OR for having a defecation frequency above baseline for ≥50 % of the time was 1·31 (95 % CI 0·98, 1·75), P=0·071, for probiotic treatment overall. Tightening the criteria for being a responder to an increase of ≥1 d/week for ≥50 % of the time resulted in an OR of 1·55 (95 % CI 1·22, 1·96), P=0·0003, for treatment overall. A treatment effect on average defecation frequency was found (P=0·0065), with the frequency being significantly higher compared with placebo at all weeks for probiotic treatment overall (all P<0·05). Effects on defecation frequency were similar for the two doses tested, suggesting that a ceiling effect was reached with the one billion dose. Overall, 4 weeks’ supplementation with the probiotic strain BB-12® resulted in a clinically relevant benefit on defecation frequency. The results suggest that consumption of BB-12® improves the GI health of individuals whose symptoms are not sufficiently severe to consult a doctor (ISRCTN18128385).

scholarly journals Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study

Gut ◽  
2018 ◽  
Vol 67 (12) ◽  
pp. 2107-2115 ◽  
Author(s):  
Sofie Ingdam Halkjær ◽  
Alice Højer Christensen ◽  
Bobby Zhao Sheng Lo ◽  
Patrick Denis Browne ◽  
Stig Günther ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Controlled Trial ◽  
Symptom Relief ◽  
Controlled Study ◽  
Faecal Microbiota ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Faecal Microbiota Transplantation ◽  
Faecal Samples ◽  
Significant Difference

ObjectiveIBS is associated with an intestinal dysbiosis and faecal microbiota transplantation (FMT) has been hypothesised to have a positive effect in patients with IBS. We performed a randomised, double-blind placebo-controlled trial to investigate if FMT resulted in an altered gut microbiota and improvement in clinical outcome in patients with IBS.DesignWe performed this study in 52 adult patients with moderate-to-severe IBS. At the screening visit, clinical history and symptoms were assessed and faecal samples were collected. Patients were randomised to FMT or placebo capsules for 12 days and followed for 6 months. Study visits were performed at baseline, 1, 3 and 6 months, where patients were asked to register their symptoms using the IBS-severity scoring system (IBS-SSS) and IBS-specific quality of life (IBS-QoL). Prior to each visit, faecal samples were collected.ResultsA significant difference in improvement in IBS-SSS score was observed 3 months after treatment (p=0.012) favouring placebo. This was similar for IBS-QoL data after 3 months (p=0.003) favouring placebo. Patients receiving FMT capsules had an increase in faecal microbial biodiversity while placebos did not.ConclusionIn this randomised double-blinded placebo-controlled study, we found that FMT changed gut microbiota in patients with IBS. But patients in the placebo group experienced greater symptom relief compared with the FMT group after 3 months. Altering the gut microbiota is not enough to obtain clinical improvement in IBS. However, different study designs and larger studies are required to examine the role of FMT in IBS.Trial registration numberNCT02788071.

scholarly journals Effects of Gut Microbiota Manipulation by Antibiotics on Host Metabolism in Obese Humans: A Randomized Double-Blind Placebo-Controlled Trial

2016 ◽  
Vol 24 (2) ◽  
pp. 341 ◽  
Author(s):  
Dorien Reijnders ◽  
Gijs H. Goossens ◽  
Gerben D.A. Hermes ◽  
Evelien P.J.G. Neis ◽  
Christina M. van der Beek ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Host Metabolism

scholarly journals Effects of Gut Microbiota Manipulation by Antibiotics on Host Metabolism in Obese Humans: A Randomized Double-Blind Placebo-Controlled Trial

2016 ◽  
Vol 24 (1) ◽  
pp. 63-74 ◽  
Author(s):  
Dorien Reijnders ◽  
Gijs H. Goossens ◽  
Gerben D.A. Hermes ◽  
Evelien P.J.G. Neis ◽  
Christina M. van der Beek ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Host Metabolism

scholarly journals Effects of Extrinsic Wheat Fiber Supplementation on Fecal Weight; A Randomized Controlled Trial

Nutrients ◽  
2020 ◽  
Vol 12 (2) ◽  
pp. 298
Author(s):  
Beate Brandl ◽  
Yu-Mi Lee ◽  
Andreas Dunkel ◽  
Thomas Hofmann ◽  
Hans Hauner ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Controlled Trial ◽  
Dry Weight ◽  
Food Products ◽  
Short Chain Fatty Acids ◽  
Normal Diet ◽  
Outcome Variable ◽  
Beneficial Effects ◽  
Wet Weight ◽  
The Impact

Higher fiber intake may confer beneficial effects on health. Our objective was to investigate the impact of 10 g extrinsic wheat fiber on fecal bulk. Therefore, we performed two randomized intervention studies in which we provided extrinsic wheat fiber-enriched products or appropriate control products for five days together with normal diet. In one trial, 10 participants received fiber-enriched food products, whereas in the second study, 19 participants supplemented their daily diet with fiber-enriched drinks. The main outcome variable of this intervention was fecal bulk. Other outcomes were gut microbiota composition, short chain fatty acids in feces, and stool consistency and frequency. Fecal wet weight was significantly increased (p < 0.02) with extrinsic wheat fiber-enriched foods. In contrast, ingestion of extrinsic wheat fiber in the form of drinks did not significantly change fecal wet weight. In both groups, fecal dry weight was not altered upon extrinsic wheat fiber supplementation. However, the intake of fiber-enriched foods resulted in higher acetic acid levels in feces compared to fiber-enriched drinks. Regarding gut microbiota profiles, extrinsic wheat fiber-enriched food products were not associated with substantial alterations. In conclusion, 10 g extrinsic wheat fiber added to a normal diet increased fecal bulk if administered in a solid food matrix, but not if applied in the form of drinks. DRKS, DRKS00015792.Registered 30 October 2018.

Effects of cranberry beverage on oxidative stress and gut microbiota in subjects with Helicobacter pylori infection: a randomized, double-blind, placebo-controlled trial

2021 ◽  
Author(s):  
Tao Gao ◽  
Meiling Hou ◽  
Bo Zhang ◽  
Xin Pan ◽  
Chengxia Liu ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Helicobacter Pylori ◽  
Gut Microbiota ◽  
Controlled Trial ◽  
Gastric Diseases ◽  
Oxidative Stress Biomarkers ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Stress Biomarkers ◽  
H Pylori

Helicobacter pylori-induced oxidative stress plays an important role in gastric diseases. H. pylori disturbs gut microbiota. The objective is to investigate the effects of cranberry beverages on oxidative stress biomarkers...

Sign in / Sign up

Export Citation Format

Share Document